Bringing treatments to life

Clinical Redefined

​

80% of life-saving innovations come from emerging biotechs, yet getting them to patients is where the system breaks down. Reaching human PoC remains painfully slow, capital-intensive, and high-risk. Investors increasingly want more human data before committing further support. And the regulatory and competitive landscape now demands that companies move faster and stay more flexible.

​

More requirements. Fewer funds. Less time.

​​

This is why I founded Vivara Clinical: to bridge the growing gap between concept and clinical proof with a faster, more cost-effective clinical strategy, so we can continue to see the best innovations help the most patients.

​​

​

Tony Xu, PhD

Managing Director, Vivara